Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) EBITDA (2022 - 2025)

TriSalus Life Sciences' EBITDA history spans 4 years, with the latest figure at -$3.3 million for Q4 2025.

  • For Q4 2025, EBITDA rose 56.85% year-over-year to -$3.3 million; the TTM value through Dec 2025 reached -$26.9 million, up 25.49%, while the annual FY2025 figure was -$26.9 million, 25.49% up from the prior year.
  • EBITDA reached -$3.3 million in Q4 2025 per TLSIW's latest filing, up from -$9.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$288273.0 in Q2 2022 to a low of -$18.6 million in Q3 2023.
  • Average EBITDA over 4 years is -$8.6 million, with a median of -$8.5 million recorded in 2024.
  • Peak YoY movement for EBITDA: tumbled 3866.38% in 2023, then skyrocketed 56.85% in 2025.
  • A 4-year view of EBITDA shows it stood at -$11.8 million in 2022, then dropped by 21.03% to -$14.2 million in 2023, then soared by 46.8% to -$7.6 million in 2024, then surged by 56.85% to -$3.3 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's EBITDA are -$3.3 million (Q4 2025), -$9.0 million (Q3 2025), and -$7.3 million (Q2 2025).